Search

everythinglearnresearchcommunity

for

Search:↓

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Adalimumab can cause complete hair loss in rare cases.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

The research found that a protein called caveolin-1 is reduced in psoriasis, but reintroducing it can help alleviate some psoriasis symptoms.

Upadacitinib may effectively treat resistant lichen planopilaris.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

New treatments like biologics and JAK inhibitors show promise for severe scalp inflammation when traditional methods fail.

A medication for skin rash also unexpectedly treated hair loss in a patient.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.

Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.

A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Dupilumab can cause lupus-like symptoms, so patients need careful monitoring.

Topical JAK inhibitors may help treat some skin conditions but need more research.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.